Printer Friendly

Articles from Chain Drug Review (February 22, 2016)

1-90 out of 90 article(s)
Title Author Type Words
'Excellent performance across enterprise' drives CVS. 1323
AARP report spotlights pricing trends. 298
ACPE elects exec committee members. 287
Adjusted earnings at Cardinal ton expectations. 743
Aeterna provides update on Zoptrex. 430
AHF files lawsuit against Gilead. 161
All eyes on FDA for biosimilar naming guidelines. 367
As new year unfolds, retail sales outlook encouraging. 393
Awards focus on antibiotic alternatives. 146
Barriers to innovation need to be shattered. 11533
Battle against 'superbugs'. 746
BD Rx business acquired by Fresenius Kabi USA. 164
Big companies eye health costs. 356
Brands help lift incontinence sales. 761
Canada Rx&D says new name highlights innovation. 356
Carlsbad adds new generics. 255
CDMA still invaluable to small retailers. Pinto, David 718
CE catalog highlights. 331
Cosentyx receives two new approvals. 102
Court nixes patents for OxyContin. 432
CVS launches first pharmacies within Target stores. 859
CVS Specialty Connect elevates adherence. 368
Diagnostic tools spur BP testing. 241
Digital platform is reconfigured by Diplomat. 202
Drug safety seen at risk. 683
Duane Reade takes cues from parent firm. 343
Enrollment on health exchanges hits 12.7 million. 480
EU faces tangle of pricing systems in regulation of generics. 650
FAST Generics Act would be step in right direction. 195
FDA prodded to clear generic drug backlog. 738
Generics market kept up momentum in 2015. 674
Glumetza dropped. 107
GPhA makes pair of exec appointments. 382
GPhA shares ideas on promoting competition. 675
Heartburn relief a common need. 860
House Committee gauges status of fledgling biosimilars market. 359
Hypertension challenge begins. 209
Impact of generic drug entries differs by country. 594
IMS Health: generics industry needs to stay focused on savings. 503
In wake of strong results, guidance for fiscal '16 reaffirmed. 400
Independents look to uphold service edge. 1413
Industry consolidation raises concern at HHS. 340
Jakeman's brings GOPO to U.S. 217
Jean Coutu unveils Health Record. 207
Like U.S., Europe tries to solve cost equation. 798
Many still favor brand-name statins. 334
Marketers sharpen focus on caregivers. 300
MarketTrack analysis: digestives. 275
MarketTrack analysis: hot/cold therapy. Brief article 264
MarketTrack analysis: probiotics. Brief article 277
McKesson teams up with mscripts. Brief article 230
Medicaid tallies savings. 510
Medication sync program is introduced by Cardinal. 349
Merck's Zepatier approved. 121
More consolidation expected in health care sector this year. 537
Mylan makes $9.9 billion offer to acquire Meda. 288
NACDS Regional Chain Conference. Conference news 171
Nature Made grows line of probiotics for specific health needs. 398
Nature's truth bets on aromatherapy. 134
NCPA seeks more pricing transparency. 386
New drug may benefit liposarcoma patients. 118
New Schick razor protects men from shave irritation. 529
No action on 21st Century Cures. Brief article 171
OneStopMeds a powerful new tool for Rexall pharmacists. 294
Opioid RX for chronic pain. Moore, Gina 780
Panzer promoted by Albertsons. 391
Personalized RX approvals on the rise. 289
Pfizer sets leadership roles for pending merger with Allergen. 477
Pharmaceutical execs speak up on Rx pricing. 732
Pharmacy chains aim to be home health care resource. 777
Pharmacy chains boost access to naloxone. 621
Pharmacy services unit is pacesetter for growth. 848
POY USA unveils 2016 winners. Brief article 267
Price swings 'wreaking havoc' on pharmacies. 289
Probiotics energize digestives. 1094
Proton pump inhibitors remain safe, CHPA says. 655
Publix taps AmerisourceBergen. 317
RediClinic forms alliance with health system. 300
Regional chains take center stage. Woldt, Jeffrey 836
Sellers alter approach as care shifts to the home. 741
Shelfbucks teams up with TimBar Packaging. Brief article 218
Solutions-driven hot/cold therapy is winning formula. 753
Specialty drug impact grows. 458
Study: generic cost hikes reflect changes in supply chain. 487
Teaming up against cancer. 936
Top generic drugs by prescriptions filled. 1178
Top multisource drugs by prescriptions filled. 1041
Walgreens takes aim at Rx abuse. 608
WBA acquisition of Rite Aid moves step closer to reality. 494
Where would we be with no generics? Coopman, Robert 425

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |